Open Payments

PETER H WIN

Type
Physician · Allopathic & Osteopathic Physicians / Ophthalmology
Where
ARCADIA, CA
NPI
1124040209
Received
$276,122 in 172 records, 2019 to 2025 ($2,854 general, $273,267 research)
As principal investigator
$4,154,135 of research payments to others in 1,314 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment16$396
2025Research payment3$11,800
2024General payment14$307
2024Research payment4$41,692
2023General payment23$529
2023Research payment6$95,996
2022General payment22$408
2022Research payment8$123,777
2021General payment31$467
2020General payment18$369
2019General payment27$376

By company

CompanyRecordsAmountYears
Genentech, Inc.15$199,7342022–2025
Hexal AG5$73,1012022–2024
SUN PHARMACEUTICAL INDUSTRIES INC.48$8542019–2025
Regeneron Pharmaceuticals, Inc.1$4312025
Novartis Pharmaceuticals Corporation20$2822019–2023
Bausch & Lomb Americas Inc.10$2102022–2025
Mallinckrodt Hospital Products Inc.8$1972021–2023
Allergan, Inc.10$1962019–2021
Alcon Vision LLC7$1612022–2025
Regeneron Healthcare Solutions, Inc.5$1442021–2024
Aerie Pharmaceuticals, Inc.7$1422019–2021
Harrow Eye, LLC4$1052025
Genentech USA, Inc.4$852022–2023
Bausch & Lomb, a division of Bausch Health US, LLC6$792019–2021
Eyevance Pharmaceuticals LLC4$602019–2022
Apellis Pharmaceuticals, Inc.2$412022–2023
Carl Zeiss Meditec AG2$382020
Alimera Sciences, Inc.3$352019–2022
Oyster Point Pharma, Inc.2$332024
Astellas Pharma US Inc1$312025
Tarsus Pharmaceuticals, Inc.1$262024
Spark Therapeutics, Inc.1$212022
bioMerieux Inc1$192025
Horizon Therapeutics plc1$182019
EyePoint Pharmaceuticals US, Inc.1$172019
Biogen, Inc.1$172023
Carl Zeiss Meditec, Inc.1$172020
Kala Pharmaceuticals, Inc.1$152019

By nature of payment

NatureRecordsAmount
Research payment21$273,267
Food and Beverage147$2,753
Gift4$101

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-27Regeneron Pharmaceuticals, Inc.$431Research paymentIn-kind items and servicesEYLEA HD Biological, OPHTHALMOLOGYA RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PA2025
2025-12-10Harrow Eye, LLC$23Food and BeverageIn-kind items and servicesVEVYE Drug, OPTOMETRY2025
2025-10-15Harrow Eye, LLC$30Food and BeverageIn-kind items and servicesVEVYE Drug, OPTOMETRY2025
2025-10-09Astellas Pharma US Inc$31Food and BeverageIn-kind items and servicesIzervay Drug, Ophthalmology2025
2025-10-02SUN PHARMACEUTICAL INDUSTRIES INC.$24Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2025
2025-08-27Alcon Vision LLC$30Food and BeverageIn-kind items and servicesRocklatan Drug, Ophthalmology2025
2025-08-01Genentech, Inc.$2,725Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2025
2025-07-30Alcon Vision LLC$25Food and BeverageIn-kind items and servicesTRYPTYR Drug, Ophthalmology2025
2025-06-12SUN PHARMACEUTICAL INDUSTRIES INC.$21Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2025
2025-04-25bioMerieux Inc$19Food and BeverageIn-kind items and services2025
2025-04-17Harrow Eye, LLC$22Food and BeverageIn-kind items and servicesVEVYE Drug, OPTOMETRY2025
2025-04-10SUN PHARMACEUTICAL INDUSTRIES INC.$23Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2025
2025-04-09Alcon Vision LLC$17Food and BeverageIn-kind items and servicesRocklatan Drug, Ophthalmology2025
2025-03-12Harrow Eye, LLC$28Food and BeverageIn-kind items and servicesVEVYE Drug, OPTOMETRY2025
2025-03-11Genentech, Inc.$8,644Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2025
2025-03-07SUN PHARMACEUTICAL INDUSTRIES INC.$17Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2025
2025-02-14Alcon Vision LLC$28Food and BeverageIn-kind items and servicesRocklatan Drug, Ophthalmology2025
2025-02-07Bausch & Lomb Americas Inc.$25Food and BeverageIn-kind items and servicesXIIDRA Drug, Ophthalmology2025
2025-02-06SUN PHARMACEUTICAL INDUSTRIES INC.$28Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2025
2024-12-18Alcon Vision LLC$23Food and BeverageIn-kind items and servicesRocklatan Drug, Ophthalmology2024
2024-12-17Genentech, Inc.$6,548Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2024
2024-11-08Bausch & Lomb Americas Inc.$23Food and BeverageIn-kind items and servicesMIEBO Drug, Ophthalmology2024
2024-10-24SUN PHARMACEUTICAL INDUSTRIES INC.$27Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2024
2024-10-23Oyster Point Pharma, Inc.$15Food and BeverageIn-kind items and servicesTYRVAYA Drug, Dry eyes2024
2024-10-05Bausch & Lomb Americas Inc.$19Food and BeverageIn-kind items and servicesVYZULTA Drug, Ophthalmology2024
2024-09-18Tarsus Pharmaceuticals, Inc.$26Food and BeverageIn-kind items and servicesXDEMVY Drug, DEMODEX BLEPHARITIS2024
2024-09-11SUN PHARMACEUTICAL INDUSTRIES INC.$25Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2024
2024-07-22Bausch & Lomb Americas Inc.$20Food and BeverageIn-kind items and servicesXIIDRA Drug, Ophthalmology2024
2024-06-25Genentech, Inc.$17,190Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2024
2024-05-23Oyster Point Pharma, Inc.$18Food and BeverageIn-kind items and servicesTYRVAYA Drug, Dry eyes2024
2024-05-08Regeneron Healthcare Solutions, Inc.$26Food and BeverageIn-kind items and servicesEYLEA Biological, OPHTHALMOLOGY2024
2024-05-02SUN PHARMACEUTICAL INDUSTRIES INC.$20Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2024
2024-04-30Bausch & Lomb Americas Inc.$16Food and BeverageIn-kind items and servicesXIIDRA Drug, Ophthalmology2024
2024-03-21Genentech, Inc.$9,855Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2024
2024-03-18Bausch & Lomb Americas Inc.$21Food and BeverageIn-kind items and servicesMIEBO Drug, Ophthalmology2024
2024-01-25Hexal AG$8,099Research paymentCash or cash equivalentCSOK583A123012024
2024-01-18SUN PHARMACEUTICAL INDUSTRIES INC.$22Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2024
2023-12-14Biogen, Inc.$17Food and BeverageIn-kind items and services2023
2023-11-30Regeneron Healthcare Solutions, Inc.$25Food and BeverageIn-kind items and servicesEYLEA HD Biological, OPHTHALMOLOGY2023
2023-10-26SUN PHARMACEUTICAL INDUSTRIES INC.$33Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2023-10-18SUN PHARMACEUTICAL INDUSTRIES INC.$5Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2023-10-16Bausch & Lomb Americas Inc.$20Food and BeverageIn-kind items and services2023
2023-09-21SUN PHARMACEUTICAL INDUSTRIES INC.$31Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2023-08-29Bausch & Lomb Americas Inc.$20Food and BeverageIn-kind items and servicesPROLENSA Drug, Ophthalmology2023
2023-08-22Genentech, Inc.$12,194Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2023
2023-08-03Novartis Pharmaceuticals Corporation$27Food and BeverageIn-kind items and servicesXIIDRA Drug, Ophthalmology2023
2023-07-06Mallinckrodt Hospital Products Inc.$25Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2023
2023-07-05Genentech, Inc.$19,133Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2023
2023-06-30Genentech USA, Inc.$23Food and BeverageIn-kind items and servicesVabysmo Drug, Immunology and Ophthalmology2023
2023-06-22SUN PHARMACEUTICAL INDUSTRIES INC.$23Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2023-06-21Genentech USA, Inc.$18Food and BeverageIn-kind items and servicesVabysmo Drug, Immunology and Ophthalmology2023
2023-06-19Bausch & Lomb Americas Inc.$21Food and BeverageIn-kind items and services2023
2023-06-15Apellis Pharmaceuticals, Inc.$19Food and BeverageCash or cash equivalentSyfovre Drug, Ophthalmology2023
2023-06-08Novartis Pharmaceuticals Corporation$30Food and BeverageIn-kind items and servicesXIIDRA Drug, Ophthalmology2023
2023-06-07SUN PHARMACEUTICAL INDUSTRIES INC.$6Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2023-05-11SUN PHARMACEUTICAL INDUSTRIES INC.$21Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2023-04-12Mallinckrodt Hospital Products Inc.$29Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2023
2023-04-12Novartis Pharmaceuticals Corporation$24Food and BeverageIn-kind items and servicesXIIDRA Drug, Ophthalmology2023
2023-04-06Alcon Vision LLC$17Food and BeverageIn-kind items and servicesRocklatan Drug, Ophthalmology2023
2023-03-29SUN PHARMACEUTICAL INDUSTRIES INC.$32Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2023-03-01Genentech, Inc.$935Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2023
2023-02-16SUN PHARMACEUTICAL INDUSTRIES INC.$26Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2023-02-07Genentech, Inc.$50,090Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2023
2023-02-07Genentech, Inc.$12,113Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2023
2023-02-07Genentech, Inc.$1,531Research paymentCash or cash equivalentFaricimab for Under represented Patients with DME2023
2023-01-19SUN PHARMACEUTICAL INDUSTRIES INC.$26Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2023
2022-12-19SUN PHARMACEUTICAL INDUSTRIES INC.$24Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2022-12-15Hexal AG$11,229Research paymentCash or cash equivalentCSOK583A123012022
2022-12-15Apellis Pharmaceuticals, Inc.$22Food and BeverageCash or cash equivalent2022
2022-12-06Genentech, Inc.$33,121Research paymentCash or cash equivalentVABYSMO Drug, Immunology and OphthalmologyFARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME2022
2022-12-06Genentech, Inc.$12,113Research paymentCash or cash equivalentVABYSMO Drug, Immunology and OphthalmologyFARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME2022
2022-12-06Genentech, Inc.$1,531Research paymentCash or cash equivalentVABYSMO Drug, Immunology and OphthalmologyFARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME2022
2022-11-21Regeneron Healthcare Solutions, Inc.$33Food and BeverageIn-kind items and servicesEYLEA Biological, OPHTHALMOLOGY2022
2022-11-01Genentech, Inc.$12,011Research paymentCash or cash equivalentVABYSMO Drug, Immunology and OphthalmologyFARICIMAB FOR UNDER REPRESENTED PATIENTS WITH DME2022
2022-10-10SUN PHARMACEUTICAL INDUSTRIES INC.$23Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2022-09-22Hexal AG$2,215Research paymentCash or cash equivalentCSOK583A123012022
2022-08-29Regeneron Healthcare Solutions, Inc.$32Food and BeverageIn-kind items and servicesEYLEA Biological, OPHTHALMOLOGY2022
2022-08-29SUN PHARMACEUTICAL INDUSTRIES INC.$5Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2022-08-16Mallinckrodt Hospital Products Inc.$18Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2022
2022-08-08SUN PHARMACEUTICAL INDUSTRIES INC.$25Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2022-06-23Hexal AG$31,475Research paymentCash or cash equivalentCSOK583A123012022
2022-06-09SUN PHARMACEUTICAL INDUSTRIES INC.$19Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2022-06-08Bausch & Lomb Americas Inc.$20Food and BeverageIn-kind items and servicesPROLENSA Drug, Ophthalmology2022
2022-05-26Mallinckrodt Hospital Products Inc.$20Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2022
2022-05-12Genentech USA, Inc.$21Food and BeverageIn-kind items and servicesSUSVIMO Drug, Immunology and Ophthalmology2022
2022-05-06Spark Therapeutics, Inc.$21Food and BeverageIn-kind items and servicesLUXTURNA Biological, OCULAR2022
2022-05-02Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesXIIDRA Drug, OPHTHALMOLOGY2022
2022-04-18Eyevance Pharmaceuticals LLC$14Food and BeverageIn-kind items and servicesFlarex Drug, OPHTHALMIC2022
2022-04-07Genentech USA, Inc.$21Food and BeverageIn-kind items and servicesSUSVIMO Drug, Immunology and Ophthalmology2022
2022-04-07SUN PHARMACEUTICAL INDUSTRIES INC.$5Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2022-03-17Hexal AG$20,080Research paymentCash or cash equivalentCSOK583A123012022
2022-03-17Alimera Sciences, Inc.$11Food and BeverageCash or cash equivalentILUVIEN Drug, OPHTHALMOLOGY2022
2022-03-10SUN PHARMACEUTICAL INDUSTRIES INC.$5Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2022-02-17SUN PHARMACEUTICAL INDUSTRIES INC.$15Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2022-02-08Alcon Vision LLC$18Food and BeverageIn-kind items and servicesSimbrinza Drug, Ophthalmology2022
2022-01-27SUN PHARMACEUTICAL INDUSTRIES INC.$5Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2022
2021-12-14Mallinckrodt Hospital Products Inc.$29Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2021
2021-12-11Mallinckrodt Hospital Products Inc.$24Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2021
2021-12-06SUN PHARMACEUTICAL INDUSTRIES INC.$20Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-11-29SUN PHARMACEUTICAL INDUSTRIES INC.$12Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-10-25Alimera Sciences, Inc.$14Food and BeverageCash or cash equivalentILUVIEN Drug, OPHTHALMOLOGY2021
2021-10-12Allergan, Inc.$14Food and BeverageIn-kind items and servicesRESTASIS MULTIDOSE Drug, DRY EYE2021
2021-10-05SUN PHARMACEUTICAL INDUSTRIES INC.$23Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-09-27SUN PHARMACEUTICAL INDUSTRIES INC.$4Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-09-20Eyevance Pharmaceuticals LLC$13Food and BeverageIn-kind items and servicesZerviate Drug, ophthalmic2021
2021-09-17Aerie Pharmaceuticals, Inc.$17Food and BeverageIn-kind items and servicesrhopressa Drug, Glaucoma2021
2021-09-13SUN PHARMACEUTICAL INDUSTRIES INC.$4Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-09-02SUN PHARMACEUTICAL INDUSTRIES INC.$21Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-08-23Novartis Pharmaceuticals Corporation$17Food and BeverageIn-kind items and servicesXIIDRA Drug, OPHTHALMOLOGY2021
2021-07-26Aerie Pharmaceuticals, Inc.$18Food and BeverageIn-kind items and servicesrocklatan Drug, Glaucoma2021
2021-07-26SUN PHARMACEUTICAL INDUSTRIES INC.$4Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-06-28Regeneron Healthcare Solutions, Inc.$25Food and BeverageIn-kind items and servicesEYLEA Biological, OPHTHALMOLOGY2021
2021-06-07SUN PHARMACEUTICAL INDUSTRIES INC.$3Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-05-24SUN PHARMACEUTICAL INDUSTRIES INC.$15Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-05-12Mallinckrodt Hospital Products Inc.$25Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2021
2021-05-10Novartis Pharmaceuticals Corporation$17Food and BeverageIn-kind items and servicesXIIDRA Drug, OPHTHALMOLOGY2021
2021-05-04Mallinckrodt Hospital Products Inc.$22Food and BeverageIn-kind items and servicesACTHAR Biological, IMMUNOLOGY2021
2021-04-19SUN PHARMACEUTICAL INDUSTRIES INC.$16Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-04-19Bausch & Lomb, a division of Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesPROLENSA Drug, Ophthalmology2021
2021-03-16Allergan, Inc.$13Food and BeverageIn-kind items and servicesCOMBIGAN Drug, OPHTHALMOLOGY2021
2021-03-01Bausch & Lomb, a division of Bausch Health US, LLC$14Food and BeverageIn-kind items and servicesPROLENSA Drug, Ophthalmology2021
2021-02-18SUN PHARMACEUTICAL INDUSTRIES INC.$7Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-02-09Allergan, Inc.$12Food and BeverageIn-kind items and servicesRESTASIS MULTIDOSE Drug, DRY EYE2021
2021-02-03Aerie Pharmaceuticals, Inc.$11Food and BeverageIn-kind items and servicesrocklatan Drug, Glaucoma2021
2021-01-28SUN PHARMACEUTICAL INDUSTRIES INC.$8Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-01-21SUN PHARMACEUTICAL INDUSTRIES INC.$9Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2021-01-13SUN PHARMACEUTICAL INDUSTRIES INC.$8Food and BeverageIn-kind items and servicesCequa Drug, Ophthalmology2021
2020-12-17SUN PHARMACEUTICAL INDUSTRIES INC.$23Food and BeverageCash or cash equivalentXELPROS Drug, Ophthalmology2020
2020-12-04SUN PHARMACEUTICAL INDUSTRIES INC.$22Food and BeverageCash or cash equivalentXELPROS Drug, Ophthalmology2020
2020-11-24Bausch & Lomb, a division of Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesPROLENSA Drug, OPHTHALMOLOGY2020
2020-11-10Allergan, Inc.$13Food and BeverageIn-kind items and servicesCOMBIGAN Drug, OPHTHALMOLOGY2020
2020-11-05Aerie Pharmaceuticals, Inc.$21Food and BeverageIn-kind items and servicesrhopressa Drug, Glaucoma2020
2020-10-06Allergan, Inc.$13Food and BeverageIn-kind items and servicesOZURDEX Drug, RETINA2020
2020-09-17Allergan, Inc.$22Food and BeverageIn-kind items and servicesRESTASIS Drug, DRY EYE2020
2020-08-24Bausch & Lomb, a division of Bausch Health US, LLC$13Food and BeverageIn-kind items and servicesPROLENSA Drug, OPHTHALMOLOGY2020
2020-08-08Bausch & Lomb, a division of Bausch Health US, LLC$12Food and BeverageIn-kind items and servicesPROLENSA Drug, OPHTHALMOLOGY2020
2020-08-06SUN PHARMACEUTICAL INDUSTRIES INC.$21Food and BeverageCash or cash equivalentXELPROS Drug, Ophthalmology2020
2020-08-03Allergan, Inc.$45GiftIn-kind items and servicesDURYSTA Drug, GLAUCOMA2020
2020-08-03Aerie Pharmaceuticals, Inc.$24Food and BeverageIn-kind items and servicesrhopressa Drug, Glaucoma2020
2020-06-15SUN PHARMACEUTICAL INDUSTRIES INC.$20Food and BeverageCash or cash equivalentBROMSITE Drug, Ophthalmology2020
2020-05-13Carl Zeiss Meditec, Inc.$17GiftIn-kind items and servicesNone Specified Medical Supply2020
2020-05-08Carl Zeiss Meditec AG$19GiftIn-kind items and servicesNone Specified Medical Supply2020
2020-05-08Carl Zeiss Meditec AG$19GiftIn-kind items and servicesNone Specified Medical Supply2020
2020-02-19Aerie Pharmaceuticals, Inc.$24Food and BeverageIn-kind items and servicesrhopressa Drug, Glaucoma2020
2020-01-27Allergan, Inc.$19Food and BeverageIn-kind items and servicesOZURDEX Drug, RETINA2020
2019-12-16Allergan, Inc.$19Food and BeverageIn-kind items and servicesOZURDEX Drug, RETINA2019
2019-12-09Eyevance Pharmaceuticals LLC$18Food and BeverageIn-kind items and servicesFlarex Drug, Ophthalmology2019
2019-12-02Aerie Pharmaceuticals, Inc.$24Food and BeverageIn-kind items and servicesRhopressa Drug, Glaucoma2019
2019-10-30SUN PHARMACEUTICAL INDUSTRIES INC.$22Food and BeverageCash or cash equivalentBROMSITE Drug, Ophthalmology2019
2019-10-30Horizon Therapeutics plc$18Food and BeverageIn-kind items and services2019
2019-10-15Bausch & Lomb, a division of Bausch Health US, LLC$11Food and BeverageIn-kind items and servicesPROLENSA Drug, OPHTHALMOLOGY2019
2019-10-03Novartis Pharmaceuticals Corporation$8Food and BeverageIn-kind items and servicesXIIDRA Drug, OPHTHALMOLOGY2019
2019-09-13SUN PHARMACEUTICAL INDUSTRIES INC.$13Food and BeverageCash or cash equivalentXELPROS Drug, Ophthalmology2019
2019-08-22Novartis Pharmaceuticals Corporation$24Food and BeverageIn-kind items and services2019
2019-08-14Novartis Pharmaceuticals Corporation$4Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-08-07Allergan, Inc.$22Food and BeverageIn-kind items and servicesOZURDEX Drug, RETINA2019
2019-08-07Novartis Pharmaceuticals Corporation$18Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-07-10Novartis Pharmaceuticals Corporation$14Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-06-27Novartis Pharmaceuticals Corporation$3Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-06-20Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-06-12Novartis Pharmaceuticals Corporation$3Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-06-06Novartis Pharmaceuticals Corporation$23Food and BeverageIn-kind items and services2019
2019-05-29Kala Pharmaceuticals, Inc.$15Food and BeverageIn-kind items and servicesINVELTYS Drug, OCULAR2019
2019-05-22Novartis Pharmaceuticals Corporation$6Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-04-17Novartis Pharmaceuticals Corporation$1Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-04-03Novartis Pharmaceuticals Corporation$5Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-03-14Eyevance Pharmaceuticals LLC$13Food and BeverageIn-kind items and servicesFlarex Drug, Ophthalmology2019
2019-03-13Novartis Pharmaceuticals Corporation$1Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-02-18Alimera Sciences, Inc.$9Food and BeverageCash or cash equivalentIluvien Drug, Ophthalmology2019
2019-02-06Novartis Pharmaceuticals Corporation$3Food and BeverageIn-kind items and servicesDUREZOL Drug, OPHTHALMOLOGY2019
2019-02-04EyePoint Pharmaceuticals US, Inc.$17Food and BeverageIn-kind items and servicesYUTIQ Drug, Chronic Non-infectious Posterior Segment Uveitis2019
2019-01-15SUN PHARMACEUTICAL INDUSTRIES INC.$23Food and BeverageCash or cash equivalentBROMSITE Drug, Ophthalmology2019

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-12-31Boehringer Ingelheim International GmbHWin Retina-Arcadia$40A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815362025
2025-12-19KYOWA KIRIN, INC.WIN RETINA$1,958A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-19KYOWA KIRIN, INC.WIN RETINA$1,958A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-19KYOWA KIRIN, INC.WIN RETINA$1,161A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-19KYOWA KIRIN, INC.WIN RETINA$2,000A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-19KYOWA KIRIN, INC.WIN RETINA$4,688A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-12KYOWA KIRIN, INC.WIN RETINA$2,865A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-12KYOWA KIRIN, INC.WIN RETINA$2,277A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-12KYOWA KIRIN, INC.WIN RETINA$2,677A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-12KYOWA KIRIN, INC.WIN RETINA$1,956A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-12KYOWA KIRIN, INC.WIN RETINA$2,865A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-12KYOWA KIRIN, INC.WIN RETINA$4,476A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-12KYOWA KIRIN, INC.WIN RETINA$5,586A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$1,393A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$1,393A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$1,393A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-12-11Regeneron Pharmaceuticals, Inc.WIN RETINA$2,554A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-11-28KYOWA KIRIN, INC.WIN RETINA$695A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-11-28KYOWA KIRIN, INC.WIN RETINA$250A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-11-27Regeneron Pharmaceuticals, Inc.WIN RETINA$1,950A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-11-27Regeneron Pharmaceuticals, Inc.WIN RETINA$1,200A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-11-27Regeneron Pharmaceuticals, Inc.WIN RETINA$1,000A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-11-27Regeneron Pharmaceuticals, Inc.WIN RETINA$7,000A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-11-27Regeneron Pharmaceuticals, Inc.WIN RETINA$2,000A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-11-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,013A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-11-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,013A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-10-31Boehringer Ingelheim International GmbHWin Retina-Arcadia$40A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815362025
2025-10-30KYOWA KIRIN, INC.WIN RETINA$39,358A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-28Boehringer Ingelheim International GmbHWin Retina-Arcadia$40A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815362025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$1,956A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$2,677A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$3,800A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$2,677A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$2,865A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$2,277A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$1,956A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$1,161A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$2,677A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$1,161A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$1,161A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$5,560A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$1,161A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$2,677A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$4,476A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-27KYOWA KIRIN, INC.WIN RETINA$2,845A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-03KYOWA KIRIN, INC.WIN RETINA$1,958A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-03KYOWA KIRIN, INC.WIN RETINA$4,104A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-03KYOWA KIRIN, INC.WIN RETINA$4,104A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-10-03KYOWA KIRIN, INC.WIN RETINA$5,586A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF KHK4951, A 2025
2025-09-30Boehringer Ingelheim International GmbHWin Retina-Arcadia$40A randomized, double-masked, placebo-controlled trial to evaluate the efficacy, safety and tolerability of oral BI1815362025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$3,105A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$3,105A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025
2025-09-17Regeneron Pharmaceuticals, Inc.WIN RETINA$2,526A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Los Angeles CountyArcadia city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Arcadia, CA, county Los Angeles County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Arcadia, CA
County
Los Angeles County, CA
State
California
Population B0100355,1709,808,66739,287,377
Population, 2020 census P156,68110,014,00939,538,223
Median age B0100243.938.237.9
Under 18 B0100120.9%20.6%22.0%
65 and over B0100120.6%15.2%15.7%
Households B1100119,2273,416,44913,548,091
Foreign born B0500246.2%33.4%27.0%
Median household income B19013$113,516$90,112$99,122
Median family income B19113$130,550$101,573$113,346
Per capita income B19301$57,549$45,792$49,513
Poverty rate B170018.6%13.7%12.0%
Unemployment rate B230255.7%7.3%6.6%
Civilian labor force B2302526,2255,200,65620,068,466
Mean commute (minutes) B0801329.330.428.7
Bachelor's degree or higher B1500357.4%36.0%37.1%
Housing units B2500120,9923,650,46614,644,735
Owner-occupied B2500358.1%45.9%55.9%
Renters B2500341.9%54.1%44.1%
Median home value B25077$1,441,800$834,200$734,700
Median gross rent B25064$2,191$1,954$2,036
White, not Hispanic B0300216.7%24.7%33.8%
Black B030021.6%7.4%5.2%
Hispanic or Latino B0300217.5%48.4%40.2%
Asian B0300258.7%14.9%15.3%
American Indian and Alaska Native B030020.5%0.2%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Arcadia, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.